How Finding Cancer Early Can Protect Your Employees — and Your Business
Our latest white paper, How Finding Cancer Early Can Protect Your Employees — and Your Business emphasizes the critical role employers play in helping drive proactive cancer screenings, highlighting the significant benefits of early cancer detection. With over 2 million Americans expected to be diagnosed with cancer in 2024,1 many of whom are within working age,2 the impact on the workforce is substantial. Employers can mitigate this by promoting a supportive culture, facilitating access to high-quality cancer care, and encouraging early cancer diagnosis by adding multi-cancer early detection (MCED) screening. By adopting proactive health management practices, companies have the potential to improve employee well-being, reduce treatment costs, and enhance productivity.
Fill out your details to get FREE access to the report now!
Additional details about the report can be found above this form.
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
- Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820
- Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2016. National Cancer Institute, 2019, based on November 2018 SEER data submission, April 2019. https://seer.cancer.gov/csr/1975_2016/